Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18955996 | METHODS OF ADMINISTERING VITAMIN A AND LACTIC ACID TO GILTS | November 2024 | June 2025 | Allow | 6 | 1 | 0 | No | No |
| 18899511 | METHOD FOR AMELIORATING OR AVOIDING THE ADVERSE EFFECTS OF EXOGENOUS GONADOTROPINS ON REPRODUCTIVE PERFORMANCE | September 2024 | April 2025 | Allow | 7 | 2 | 0 | No | No |
| 18443769 | GDNF FUSION POLYPEPTIDES AND METHODS OF USE THEREOF | February 2024 | April 2025 | Allow | 14 | 1 | 0 | No | No |
| 18442889 | Human Anti-SOD1 Antibodies | February 2024 | March 2026 | Abandon | 25 | 1 | 1 | No | No |
| 18529590 | METHODS FOR PROMOTING WOUND HEALINGAND HAIR GROWTH COMPRISING GDNF ADMINISTRATION | December 2023 | March 2025 | Allow | 15 | 1 | 1 | No | No |
| 18457127 | TREATMENT OF VESTIBULAR VERTIGO USING BOTULINUM TOXINS | August 2023 | February 2026 | Allow | 30 | 2 | 0 | Yes | No |
| 18226206 | RECOMBINANT FSH COMPOSITION FOR CONTROLLED OVARIAN STIMULATION | July 2023 | February 2026 | Allow | 31 | 3 | 0 | No | No |
| 18347143 | ENDO-S2 MUTANTS AS GLYCOSYNTHASES, METHOD OF MAKING AND USE FOR GLYCOENGINEERING OF GLYCOPROTEINS | July 2023 | August 2025 | Allow | 25 | 2 | 0 | No | No |
| 18138000 | STABLE LIQUID GONADOTROPIN FORMULATION | April 2023 | December 2024 | Allow | 20 | 1 | 0 | No | No |
| 18299458 | FUSION PROTEINS COMPRISING PROGRANULIN | April 2023 | February 2025 | Abandon | 23 | 0 | 1 | No | No |
| 18153944 | TICK CHEMOKINE BINDING PROTEINS FOR USE IN THERAPY AND DIAGNOSIS | January 2023 | November 2024 | Abandon | 23 | 1 | 1 | No | No |
| 17999313 | SELF-ASSEMBLING PEPTIDE | November 2022 | March 2026 | Allow | 40 | 1 | 0 | Yes | No |
| 18052485 | MULLERIAN INHIBITING SUBSTANCE (MIS) PROTEINS FOR OVARIAN AND UTERINE ONCOPROTECTION, AND OVARIAN RESERVE AND UTERINE PRESERVATION | November 2022 | August 2025 | Allow | 37 | 2 | 1 | No | No |
| 17922977 | TREATMENT OF CORONAVIRUS INFECTION WITH FLT3 RECEPTOR INTERACTING LECTIN (FRIL) | November 2022 | January 2026 | Allow | 38 | 1 | 0 | No | No |
| 17923108 | PEPTIDES AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | November 2022 | March 2026 | Abandon | 41 | 1 | 0 | No | No |
| 17921242 | NEUROGENIC TISSUE NANOTRANSFECTION IN THE MANAGEMENT OF CUTANEOUS DIABETIC POLYNEUROPATHY | October 2022 | December 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17937110 | METHODS OF INCREASING ENDOGENOUS LUTEINIZING HORMONE | September 2022 | May 2025 | Abandon | 32 | 2 | 0 | No | No |
| 17915247 | Early Drug Interventions to Reduce COVID-19 Related Respiratory Distress, Need for Respirator Assist and Death | September 2022 | December 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17942763 | PSILOCYBIN COMPOSITIONS | September 2022 | April 2025 | Abandon | 31 | 2 | 0 | No | No |
| 17823937 | NEOANTIGEN VACCINES FOR TRIPLE NEGATIVE BREAST CANCER | August 2022 | November 2024 | Allow | 27 | 1 | 1 | No | No |
| 17802164 | Anti-ADM-antibodies binding to the free N-terminus for accelerated transition of ADM-Gly to bio-ADM in patients with ADM-Gly/ bio-ADM ratio above a threshold and combination with vitamin C | August 2022 | February 2026 | Allow | 42 | 2 | 0 | No | No |
| 17880962 | BOTULINUM TOXIN FOR USE IN TREATMENT OF AUTISM SPECTRUM DISORDERS | August 2022 | November 2024 | Allow | 27 | 2 | 0 | No | No |
| 17797229 | METHODS FOR TREATING PULMONARY HYPERTENSION WITH AN ACTRIIB VARIANT POLYPEPTIDE | August 2022 | February 2026 | Abandon | 42 | 2 | 0 | No | No |
| 17817274 | RECOMBINANT FSH COMPOSITION FOR TREATMENT OF INFERTILITY | August 2022 | July 2025 | Abandon | 36 | 3 | 0 | No | No |
| 17879330 | ASSAYS AND METHODS FOR TARGETED TREATMENT OF HYDROSALPINX | August 2022 | January 2025 | Allow | 29 | 2 | 1 | No | No |
| 17759740 | RECOMBINANT PROTEIN FOR NEUTERING OR SPAYING ANIMAL, AND VACCINE COMPOSITION COMPRISING SAME | July 2022 | October 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17815749 | COMPOSITIONS AND METHODS FOR ANTI-PACAP ANTIBODIES | July 2022 | November 2024 | Allow | 28 | 1 | 1 | No | No |
| 17863028 | Antagonist Antibodies Directed Against Calcitonin Gene-Related Peptide and Methods Using Same | July 2022 | January 2025 | Abandon | 30 | 1 | 1 | No | No |
| 17783801 | METHODS AND SYSTEMS FOR TREATING PREGNANCY-RELATED HYPERTENSIVE DISORDERS COMPRISING ANTI-sENG AND ANTI-sFLT-1 ANTIBODIES | June 2022 | December 2025 | Allow | 42 | 2 | 0 | No | No |
| 17782515 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY HYPERTENSION | June 2022 | August 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17779504 | TREATMENT FOR PHYSIOLOGICAL IRON OVERLOAD WITH AN ANTI-MATRIPTASE-2 ANTIBODY | May 2022 | October 2025 | Allow | 41 | 1 | 0 | No | No |
| 17745409 | METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES WITH NATALIZUMAB | May 2022 | December 2025 | Allow | 43 | 1 | 0 | No | No |
| 17716754 | METHODS OF REDUCING SYMPTOMS OF OPIOID WITHDRAWAL SYNDROME AND RISK OF RELAPSE TO DRUG SEEKING | April 2022 | June 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17765883 | USE OF GDF15 FOR TREATING CARDIOMETABOLIC SYNDROME AND OTHER CONDITIONS | April 2022 | November 2025 | Allow | 44 | 2 | 0 | No | No |
| 17710756 | ASSESSMENT OF PREECLAMPSIA USING ASSAYS FOR FREE AND DISSOCIATED PLACENTAL GROWTH FACTOR | March 2022 | November 2024 | Abandon | 32 | 2 | 0 | No | No |
| 17765270 | ANTI-PD-L1 ANTIGEN BINDING PROTEIN AND APPLICATION THEREOF | March 2022 | February 2026 | Allow | 46 | 1 | 1 | No | No |
| 17709305 | HUMAN-DERIVED RECOMBINANT FSH FOR CONTROLLED OVARIAN | March 2022 | September 2024 | Allow | 30 | 2 | 1 | No | No |
| 17696920 | DIMER IMMUNOADHESIN, PHARMACEUTICAL COMPOSTION AND USE THEREOF | March 2022 | June 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17761051 | ENGINEERED RECEPTORS FOR HUMAN CYTOMEGALOVIRUS AND USES THEREOF | March 2022 | November 2025 | Allow | 44 | 2 | 0 | No | No |
| 17642773 | AUTOANTIBODY SPECIFICALLY BINDING TO NELL-1 AND ELEVATED NELL-1 POLYPEPTIDE LEVELS FOR IDENTIFYING AND TREATING MEMBRANOUS NEPHROPATHY | March 2022 | January 2026 | Allow | 46 | 2 | 0 | Yes | No |
| 17640997 | Composition for Preventing or Treating Salivary Gland Diseases Using Cell-Derived Vesicle | March 2022 | October 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17636396 | SCARA5 AND DIO2 AS BIOMARKERS FOR MISCARRIAGE AND IMPLANTATION FAILURE | February 2022 | February 2026 | Allow | 48 | 2 | 1 | No | No |
| 17672172 | Methods for Treating Conditions by Restoring Central Nervous System Endocrine Gland Function, and Compositions and Devices for Practicing the Same | February 2022 | March 2025 | Abandon | 37 | 3 | 1 | No | No |
| 17628495 | Methods Of Preventing Or Treating Fatty Degeneration Of Skeletal Muscle | January 2022 | February 2026 | Allow | 49 | 4 | 0 | No | No |
| 17626661 | COMPOSITION AND METHODS FOR IMPROVING THICKNESS AND RECEPTIVITY OF ENDOMETRIAL LINING | January 2022 | December 2025 | Abandon | 47 | 0 | 1 | No | No |
| 17625528 | Refining Method of Ophthalmic Aflibercept | January 2022 | October 2025 | Allow | 45 | 1 | 0 | No | No |
| 17625212 | PEGylated synthetic KL4 peptide, Compositions and Methods Thereof | January 2022 | December 2025 | Allow | 47 | 1 | 0 | No | No |
| 17624309 | NEUTRALIZING ANTI-AMYLOID BETA ANTIBODIES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | December 2021 | January 2026 | Allow | 49 | 1 | 1 | No | No |
| 17618112 | CORRECTING PROTEIN MISFOLDING IN DIABETES | December 2021 | September 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17544579 | METHODS FOR TREATING MUSCLE WASTING AND BONE DISEASE USING NOVEL HYBRID ACTRIIB LIGAND TRAP PROTEINS | December 2021 | August 2024 | Allow | 32 | 2 | 1 | No | No |
| 17530587 | Anti-Human Transferrin Receptor Antibody Permeating Blood-Brain Barrier | November 2021 | March 2026 | Abandon | 52 | 1 | 1 | No | No |
| 17529045 | Clonal Hematopoiesis and Risk of Chronic Liver Disease | November 2021 | November 2025 | Abandon | 48 | 4 | 1 | No | No |
| 17611706 | ENDOMETRIAL RECEPTIVITY DETERMINATION | November 2021 | February 2026 | Allow | 51 | 2 | 1 | No | No |
| 17608427 | Novel Selective ACKR3 Modulators and Uses Thereof | November 2021 | November 2025 | Allow | 48 | 1 | 1 | No | No |
| 17607218 | ASSOCIATION OF POLYCLONAL ANTIBODIES AND ANTI-PD1 OR ANTI-PDL1 ANTIBODIES FOR THE TREATMENT OF CANCER | October 2021 | October 2025 | Allow | 48 | 2 | 1 | No | No |
| 17500741 | ANTI-MERTK ANTIBODIES AND THEIR METHODS OF USE | October 2021 | May 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17600344 | Biomarker Pairs of Preterm Birth | September 2021 | March 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17488906 | METHOD FOR DETECTING IMMINENT CHILDBIRTH | September 2021 | April 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17442593 | MULTISPECIFIC AGENTS FOR TREATMENT OF CANCER | September 2021 | June 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17440930 | KIT FOR DETECTING SOLUBLE GROWTH STIMULATION EXPRESSED GENE 2 PROTEIN | September 2021 | September 2025 | Allow | 48 | 1 | 1 | No | No |
| 17439065 | SMALL SHEDDING BLOCKING AGENTS | September 2021 | August 2025 | Allow | 47 | 2 | 0 | No | No |
| 17437065 | ADAM17 BINDING MOLECULES AND USES THEREOF | September 2021 | March 2025 | Allow | 43 | 1 | 0 | No | No |
| 17436582 | A COMBINATION OF BIOMARKERS FOR DIAGNOSING OF DIABETIC RETINOPATHY AND USE THEREOF | September 2021 | January 2026 | Abandon | 52 | 2 | 1 | No | No |
| 17463876 | DYNAMIC OF SFLT-1 OR ENDOGLiN/PIGF RATIO AS AN INDICATOR FOR IMMINENT PREECLAMPSIA AND/OR HELLP SYNDROME | September 2021 | March 2025 | Allow | 42 | 3 | 0 | No | No |
| 17435169 | COMPOSITIONS COMPRISING AT LEAST ONE IONIC LIQUID, A POLYPEPTIDE AND AT LEAST ONE NON-IONIC SURFACTANT FOR PROTEIN DELIVERY | August 2021 | July 2025 | Allow | 46 | 2 | 1 | No | No |
| 17446369 | METHOD FOR EVALUATING URINE OF A SUBJECT TO ESTIMATE THE FERTILE WINDOW BY EVALUATING FOR THE PRESENCE OF ANALYTES OF ESTROGEN AND PROGESTERONE | August 2021 | August 2024 | Allow | 36 | 3 | 0 | No | No |
| 17432744 | PERIPHERAL BLOOD BIOMARKER FOR EVALUATING ANTI-TUMOR IMMUNE EFFECT OF RADIATION THERAPY | August 2021 | July 2025 | Allow | 47 | 2 | 0 | No | No |
| 17432265 | CD33 ANTIBODIES AND METHODS OF USING THE SAME TO TREAT CANCER | August 2021 | February 2025 | Allow | 42 | 1 | 0 | No | No |
| 17430490 | BIOMARKERS FOR DIAGNOSIS OF OCULAR DISEASES AND THE METHOD THEREOF | August 2021 | November 2025 | Abandon | 51 | 2 | 0 | No | No |
| 17429602 | VARIABLE LYMPHOCYTE RECEPTORS THAT TARGET THE BLOOD BRAIN BARRIER AND METHODS OF USE | August 2021 | March 2025 | Allow | 43 | 1 | 0 | No | No |
| 17427208 | MULTISPECIFIC ANTIBODIES HAVING SPECIFICITY FOR TNFA AND IL-17A, ANTIBODIES TARGETING IL-17A, AND METHODS OF USE THEREOF | July 2021 | June 2025 | Allow | 47 | 2 | 0 | No | No |
| 17422353 | SYSTEMS AND METHODS FOR VESICLE CARGO LABELING AND DETECTION | July 2021 | May 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17371436 | AUTOLOGOUS SOMATIC STEM CELL THERAPY, METHOD OF CONTROLLABLE PREPARATION OF THERAPEUTIC COMPOSITION AND PROCEDURE OF ADAPTIVE TREATMENT OF IVF PATIENT | July 2021 | April 2025 | Allow | 45 | 4 | 1 | No | No |
| 17422102 | IN VITRO METHOD FOR THE DIAGNOSIS OR PROGNOSIS OF NEURODEGENERATIVE DISORDERS | July 2021 | February 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17352898 | BIOMARKERS AND METHODS FOR PREDICTING PRETERM BIRTH | June 2021 | November 2025 | Allow | 53 | 5 | 1 | No | No |
| 17415031 | METHODS OF USING BUTYROPHILIN ANTIBODIES FOR TREATING HIV INFECTION | June 2021 | January 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17311538 | A METHOD OF DETERMINING RISK FOR SKIN CANCER DEVELOPMENT AND SKIN CANCER THERAPEUTIC PREVENTION BY MEASURING PD-1/PD-L1 SIGNALING PATHWAY MEMBERS | June 2021 | May 2025 | Allow | 47 | 2 | 0 | Yes | No |
| 17311509 | USE OF CD26 AND CD39 AS NEW PHENOTYPIC MARKERS FOR ASSESSING MATURATION OF FOXP3+ T CELLS AND USES THEREOF FOR DIAGNOSTIC PURPOSES | June 2021 | December 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17298513 | BIOMARKER FOR DIAGNOSING AT-RISK MENTAL STATE | May 2021 | September 2025 | Abandon | 52 | 2 | 1 | No | No |
| 17296941 | BLOOD-BASED SIGNATURES FOR DIAGNOSIS AND SUB-TYPING OF INFLAMMATORY BOWEL DISEASE SUBSETS | May 2021 | July 2025 | Allow | 50 | 2 | 1 | Yes | No |
| 17291858 | COMPOSITIONS AND METHODS OF PROGNOSIS AND CLASSIFICATION FOR PREECLAMPSIA | May 2021 | February 2025 | Allow | 46 | 1 | 1 | No | No |
| 17232513 | PREECLAMPSIA SCREENING DEVICE AND METHODS MEASURING ACTIVIN AND/OR INHIBIN A | April 2021 | December 2024 | Allow | 44 | 4 | 1 | Yes | No |
| 17285314 | COMPOSITIONS AND METHODS FOR CONTROLLED OVARIAN STIMULATION | April 2021 | January 2025 | Allow | 46 | 3 | 0 | No | No |
| 17284302 | DETECTING TUMOR MUTATION BURDEN WITH RNA SUBSTRATE | April 2021 | November 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17282854 | KIDNEY HEALTH MONITORING IN HYPERTENSION PATIENTS | April 2021 | January 2026 | Allow | 58 | 2 | 1 | No | No |
| 17282307 | IMMUNOASSAY AND MEASUREMENT REAGENT FOR LEUCINE-RICH ALPHA2 GLYCOPROTEIN | April 2021 | November 2024 | Allow | 43 | 1 | 1 | Yes | No |
| 17277179 | METHOD AND KIT FOR DETERMINING POSSIBILITY OF ONSET OF IGA NEPHROPATHY | March 2021 | January 2026 | Abandon | 58 | 4 | 0 | No | No |
| 17044220 | COMPOSITION FOR CONTROLLED OVARIAN STIMULATION | September 2020 | February 2025 | Abandon | 53 | 4 | 1 | No | No |
| 16638179 | METHOD OF IDENTIFYING LAUNDRY MALODOR, MOLDY MALODOR AND/OR SWEAT MALODOR MODULATING COMPOUNDS | February 2020 | December 2024 | Abandon | 58 | 2 | 1 | No | Yes |
| 16603952 | DETECTION OF PREDICTORS OF PREECLAMPSIA | October 2019 | November 2024 | Abandon | 60 | 3 | 1 | No | No |
| 16488935 | Determining Toxicity Risk in CAR T-Cell Therapy | August 2019 | July 2024 | Allow | 59 | 3 | 1 | No | No |
| 16468073 | METHOD OF DIAGNOSIS OF THE AESTHETIC QUALITIES OF THE SKIN | June 2019 | February 2025 | Allow | 60 | 4 | 1 | No | No |
| 16343624 | DOSE DETERMINATION FOR IMMUNOTHERAPEUTIC AGENTS | April 2019 | May 2025 | Abandon | 60 | 6 | 1 | No | No |
| 16242519 | COMPOSITIONS, DEVICES, AND METHODS OF DEPRESSION SENSITIVITY TESTING | January 2019 | September 2024 | Allow | 60 | 6 | 1 | No | Yes |
| 16088785 | METHOD FOR EXTRACORPOREAL TREATMENT OF PREECLAMPSIA AND RELATED DISORDERS | September 2018 | January 2025 | Allow | 60 | 10 | 1 | No | No |
| 15777547 | RECOMBINANT HUMAN C1 ESTERASE INHIBITOR AND USES THEREOF | May 2018 | September 2024 | Allow | 60 | 8 | 1 | No | No |
| 15889261 | Detection and Treatment of Pregnancy Complications Comprising Determining Sialyl Lewis Antigens and Administering hCG | February 2018 | October 2019 | Allow | 20 | 2 | 0 | No | No |
| 15285240 | METHODS AND COMPOSITIONS FOR MANAGING REPRODUCTION | October 2016 | January 2020 | Allow | 39 | 3 | 1 | Yes | No |
| 15079503 | METHOD FOR DIAGNOSING FIBROMYALGIA SYNDROME, AND KIT THEREFOR | March 2016 | August 2018 | Allow | 28 | 2 | 1 | Yes | No |
| 14773677 | PRE-ECLAMPSIA BIOMARKERS | September 2015 | March 2018 | Allow | 30 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BORGEEST, CHRISTINA M.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 42.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner BORGEEST, CHRISTINA M works in Art Unit 1675 and has examined 152 patent applications in our dataset. With an allowance rate of 84.9%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 43 months.
Examiner BORGEEST, CHRISTINA M's allowance rate of 84.9% places them in the 61% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by BORGEEST, CHRISTINA M receive 2.36 office actions before reaching final disposition. This places the examiner in the 67% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by BORGEEST, CHRISTINA M is 43 months. This places the examiner in the 16% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +12.5% benefit to allowance rate for applications examined by BORGEEST, CHRISTINA M. This interview benefit is in the 49% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 31.8% of applications are subsequently allowed. This success rate is in the 66% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 59.4% of cases where such amendments are filed. This entry rate is in the 85% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 87% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 71% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 19.7% of allowed cases (in the 98% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 6.2% of allowed cases (in the 83% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.